IL288838B1 - Process for preparing oligonucleotides using a modified oxidation protocol - Google Patents
Process for preparing oligonucleotides using a modified oxidation protocolInfo
- Publication number
- IL288838B1 IL288838B1 IL288838A IL28883821A IL288838B1 IL 288838 B1 IL288838 B1 IL 288838B1 IL 288838 A IL288838 A IL 288838A IL 28883821 A IL28883821 A IL 28883821A IL 288838 B1 IL288838 B1 IL 288838B1
- Authority
- IL
- Israel
- Prior art keywords
- equivalents
- oxidation
- days
- formula
- nucleoside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Description
WO 2020/249571 PCT/EP2020/065992 Process for the preparation of oligonucleotides using modified oxidation protocol.
The invention relates to a novel process for the production of a mixed P=O/P=S backbone oligonucleotide comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme ' nucleoside residue 5' nucleoside residue 3' nucleoside residue 3' nucleoside residue I 11 wherein the oxidation follows a particular oxidation protocol.
The oligonucleotide synthesis in principle is a stepwise addition of nucleotide residues to the 5'-terminus of the growing chain until the desired sequence is assembled.
As a rule, each addition is referred to as a synthetic cycle and in principle consists ofthe chemical reactions a!) de-blocking the protected hydroxyl group on the solid support, a2) coupling the first nucleoside as activated phosphoramidite with the free hydroxyl group on the solid support, a3) oxidizing or sulfurizing the respective P-linked nucleoside (phosphite triester) to form the respective phosphodiester (P=O) or the respective phosphorothioate (P=S); WO 2020/249571 PCT/EP2020/065992 -2- a4) optionally, capping any unreacted hydroxyl groups on the solid support; as) de-blocking the 5’ hydroxyl group of the first nucleoside attached to the solid support; a6) coupling the second nucleoside as activated phosphoramidite to form the respective P-linked dimer; a?) oxidizing or sulfurizing the respective P-linked dinucleotide (phosphite triester) to form the respective phosphodiester (P=O) or the respective phosphorothioate (P=S); as) optionally, capping any unreacted 5’ hydroxyl groups; a9) repeating the previous steps as to as until the desired sequence is assembled.
The principles of the oligonucleotide synthesis are well known in the art (see e.g. Oligonucleotide synthesis; Wikipedia, the free encyclopedia; https://en.wikipedia.org/wiki/Oligonucleotide synthesis, of March 15, 2016).
The oxidizing step is typically performed with an oxidation solution comprising iodine, an organic solvent, which as a rule is pyridine and water.
However, it was observed that when a freshly prepared oxidation solution has been applied, not only the desired oxidation of the intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II takes place, but also, as a side reaction, phosphorothioate internucleotide linkages present in the molecule may be affected by a P=S to P=O conversion at the internucleotide linkages which resulted in a higher than expected content of phosphodiester linkages within the compound of formula II.
Object of the invention therefore was to find an oxidation protocol which allows a selective oxidation of the phosphite triester compound of formula I into the phosphodiester compound of formula II without affecting the phosphorothioate internucleotide linkage.
It was found that the object of the invention could be reached with the process for the production of a mixed P=O/P=S backbone oligonucleotide which comprises the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme WO 2020/249571 PCT/EP2020/065992 ' nucleoside residue 5' nucleoside residue 3' nucleoside residue3' nucleoside residue III with an oxidation solution obtained by mixing iodine, an organic solvent, and water , and which is characterized in that the oxidation solution has been aged for a time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
The term "Ci-6-alkyl" denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms, and in a more particular embodiment 1 to 4 carbon atoms. Typical examples include methyl, ethyl, propyl, isopropyl, n-butyl, z-butyl, sec-butyl, or t- butyl, preferably methyl or ethyl.
The term oligonucleotide as used herein is defined as it is generally understood by the skilled person as a molecule comprising two or more covalently linked nucleotides. For use as a therapeutically valuable oligonucleotide, oligonucleotides are typically synthesized as to 40 nucleotides, preferably 10 to 25 nucleotides in length.
The oligonucleotides may consist of optionally modified DNA or RNA nucleoside monomers or combinations thereof.
Optionally modified as used herein refers to nucleosides modified as compared to the equivalent DNA or RNA nucleoside by the introduction of one or more modifications of the sugar moiety or the nucleobase moiety.
Typical modifications can be the 2،-O-(2-Methoxyethyl)-substitution (2’-M0E) substitution in the sugar moiety or the locked nucleic acid (LNA), which is a modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and the 4' carbon.
WO 2020/249571 PCT/EP2020/065992 -4- The term modified nucleoside may also be used herein interchangeably with the term "nucleoside analogue" or modified "units" or modified "monomers".
The DNA or RNA nucleotides are as a rule linked by a phosphodiester (P=O) or a phosphorothioate (P=S) internucleotide linkage which covalently couples two nucleotides together.
In accordance with the invention at least one internucleotide linkage has to consist of a phosphorothioate (P=S). Accordingly, in some oligonucleotides all other internucleotide linkages may consist of a phosphodiester (P=O) or in other oligonucleotides the sequence of internucleotide linkages vary and comprise both phosphodiester (P=O) and phosphorothioate (P=S) intemucleotide linkages.
Accordingly the term mixed P=O/P=S backbone oligonucleotide refers to oligonucleotides wherein at least one intemucleotide linkage has to consist of a phosphorothioate (P=S).
The nucleobase moieties may be indicated by the letter code for each corresponding nucleobase, e.g. A, T, G, C or U, wherein each letter may optionally include modified nucleobases of equivalent function. For example, in the exemplified oligonucleotides, the nucleobase moieties are described with capital letters A, T, G and MeC (5-methyl cytosine) for LNA nucleoside and with small letters a, t, g, c and MeC for DNA nucleosides. Modified nucleobases include but are not limited to nucleobases carrying protecting groups such as tert-butylphenoxyacetyl, phenoxyacetyl, benzoyl, acetyl, isobutyryl or dimethylformamidino (see Wikipedia, Phosphoramidit-Synthese, https://de.wikipedia.org/wiki/Phosphoramidit- Synthese of March 24, 2016).
Preferably the oligonucleotide consists of optionally modified DNA or RNA nucleoside monomers or combinations thereof and is 10 to 40, preferably 10 to nucleotides in length.
The principles of the oligonucleotide synthesis are well known in the art (see e.g. Oligonucleotide synthesis; Wikipedia, the free encyclopedia; https://en.wikipedia.org/wiki/Oligonucleotide synthesis, of March 15, 2016).
Larger scale oligonucleotide synthesis nowadays is carried out in an automated manner using computer-controlled synthesizers.
WO 2020/249571 PCT/EP2020/065992 -5- As a rule, oligonucleotide synthesis is a solid-phase synthesis, wherein the oligonucleotide being assembled is covalently bound, via its 3'-terminal hydroxy group, to a solid support material and remains attached to it over the entire course of the chain assembly. Suitable supports are the commercial available macroporous polystyrene supports like the Primer support 5G from GE Healthcare or the NittoPhase®HL support from Kinovate.
The subsequent cleavage from the resin can be performed with concentrated aqueous ammonia. The protecting groups on the phosphate and the nucleotide base are also removed within this cleavage procedure.
As outlined above the process for the production of a mixed P=O/P=S backbone oligonucleotide is comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme ' nucleoside residue 5' nucleoside residue 3' nucleoside residue3' nucleoside residue I H with an oxidation solution obtained by mixing iodine, an organic solvent, and water and is characterized in that the oxidation solution has been aged for a time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
The mixed P=O/P=S backbone oligonucleotide comprises at least one phosphorothioate intemucleotide linkage.
The oxidation solution is typically a solution which can be obtained by mixing iodine, an organic solvent, and water.
The organic solvent can be selected from pyridine or from a C1-6 alkyl-substituted pyridine e.g. lutidine, but preferably from pyridine. A further organic solvent such as tetrahydrofuran may be present.
WO 2020/249571 PCT/EP2020/065992 -6- The oxidation solutions are commercially available, e.g. as oxidizer solutions from Sigma Aldrich (Merck). Alternatively, fresh solutions can be prepared using commercially available iodine and pyridine.
The volume ratio of pyridine or C1-6 alkyl-substituted pyridine to water can vary in a range from 1:1 to 20:1, preferably from to 5:1 to 15:, but more preferably is 9:1 .
The iodine concentration in the oxidation solution can be in the range of 10 mM to 100 mM, more preferably in the range between 20 mM to 50 mM.
The optimal period for the aging is largely determined by the temperature at which the oxidation solution is aged. While a low aging temperature results in longer aging period, a higher aging temperature significantly reduces the aging time.
It was found that the aging of the oxidation solution can take place at a temperature of °C to 100 °C, but preferably at a temperature of 30 °C to 60 °C.
The time period required for the aging of the oxidation solution has to be sufficient to effect selective oxidation of the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate internucleotide linkages.
As a rule the oxidation solution can be aged for a time period of at least 1 day, 3 days, days, 10 days, 15 days or at least 20 days.
The time period may, as mentioned, largely varies dependent on the aging temperature and can for an aging temperature of 30 °C to 35 °C vary between 10 days and 150 days, more typically between 20 days and 60 days, while for an aging temperature of °C to 65 °C can vary between 1 day and 30 days, more typically between 2 and 15 days.
The aging as a rule goes along with an increase of the conductivity (uS/cm) and a decrease of the pH. In a further embodiment of the invention the process of the present invention comprises the monitoring of the parameters pH and conductivity to determine the time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without oxidizing the phosphorothioate intemucleotide linkages.
WO 2020/249571 PCT/EP2020/065992 -7- The amount of oxidant used in the oxidation reaction can be selected between 1.equivalents and 15 equivalents , more preferably between 1.5 equivalents and 4.5 equivalents, most preferably between 2 equivalents and 4 equivalents.
As a rule the oxidation reaction temperature is performed between 15 °C and 27 °C, more preferably between 18 °C and 24 °C.
By way of illustration the oligonucleotide can be selected from: ' - MeCs MeU0 MeC0A0GsTsAsAs MeCsAsTsTsGsAs MeCsA0 MeC0 MeC0As MeC- 3׳ The underlined residues are 2'-M0E nucleosides. The locations of phosphorothioate and phosphate diester linkages are designated by S and O, respectively. It should be noted that 2'- O-(2-methoxyethyl)-5-methyluridine (2'-M0E MeU) nucleosides are sometimes referred to as 2'-O-(2-methoxyethyl)ribothymidine (2'-M0E T).
The compounds disclosed herein have the following nucleobase sequences SEQ ID No. 1: cucagtaacattgacaccac WO 2020/249571 PCT/EP2020/065992 -8- Examples Example 1 Synthesis of 5' - MeCs MeU0 MeC0A0GsTsAsAs MeCs AsTsTsGsAs MeCsA0 MeC0 MeC0As MeC-3' The oligonucleotide was produced by standard phosphoramidite chemistry on solid phase at a scale of 2.20 mmol using an AKTA Oligopilot 100 and Primer Support Unylinker (NittoPhase LH Unylinker 330). In general 1.4 equiv of the DNA/2’-MOE-phosphoramidites were employed. Other reagents (dichloroacetic acid, 1-methylimidazole, 4,5- dicyanoimidazole, acetic anhydride, phenylacetyl disulfide, pyridine, triethylamine) were used as received from commercially available sources and reagent solutions at the appropriate concentration were prepared (see table 1 below) Cleavage and deprotection was achieved using ammonium hydroxide to give the crude oligonucleotide.
Table 1: Standard Reagent Solutions Deblock 10% dichloroacetic acid in toluene (v/v)Phosphoranudites 0.2 M in acetonitrileWil 1)( 1 aclnalor 1.0 M 4,5-dicyanoimidazole/ 0.1 M 1-methylimidazole in acetonitrileO1d1/er 0.05 M iodine in pyridine/water 9:1 (v/v); purchased from Sigma Aldrich or freshly prepared (see examples)Thiolalion 0.2 M phenylacetyl disulfide in 3-picoline/acetonitrile (1:1 v/v)( ap 1-Methylimidazole/pyridine/acetonitrile 2:3:5 (v/v/v)( ap B Acetic anhydride/acetonitrile 1:4 (v/v)1n1nc wash 50% triethylamine in acetonitrile (v/v)( leaxagcand Deprotection 28-32% aqueous ammonium hydroxide Example 2 Oxidizer aging experiments Example 2.1with purchased oxidizer solution WO 2020/249571 PCT/EP2020/065992 -9- Table 2: Oxidizer Batch 1 Oxidizer Batch 2Example Aging time at 30-35 JC (d)Total (P=O) ; content(%)Example Aging time at 30-35X (d)Total (P=O) ; content(%) 2.1 O1 7.8 3.1 O1 14.82.2 3 3.5 3.2 3 9.32.3 6 1.8 3.3 6 4.52.4 9 1.7 3.4 9 3.42.5 162 4.5 3.5 162 11.6 1 refers to the point in time when an aliquot from the commercial solution was taken for use-test and the thermal treatment of the remainder of the solution was started. This is not the same as the preparation time of the solution.the solution was not aged at 30-35 °C but stored at 1-15 °C starting at t = 0.refers to the percentage of molecules having a mass difference of 16 Da relative to the molecular mass of the desired compound determined in mass spectrometry, i.e. percentage of those molecule wherein 1 P=S linkage has been transformed into a P=O linkage.
Example 2.2with freshly prepared oxidizer solution: a) Preparation of iodine solution 1 .00 kg of water were added to 8.00 kg of pyridine at room temperature. 127 g of iodine were added. 0.827 kg of pyridine were added for rinsing and the mixture was stirred for 1 h under a positive pressure of dry nitrogen. b) Aging of iodine solution • Aging at 30-35 °C:800 mL aliquots were stored at 30-35 °C in amber glass bottles until use.• Aging at 60-65 °C:The material was kept in a jacketed glass reactor at 60-65 °C under a positive pressure of dry nitrogen until use.
WO 2020/249571 PCT/EP2020/065992 -10- Table 3: (aging at 30 °C-35 °C) Oxidizer Batch aged at 30 JC to 35 JCExample Aging time at 30-35 JC (d)Total (P=O).! content(%)PH Conductivity (uS/cm)2.6 O1 15.0 7.31 1862.7 9 8.2 6.38 11442.8 17 4.3 6.33 14402.9 29 2.0 6.21 15763.0 59 1.5 6.35 16543.1 122 1.2 6.18 1633 Table 4 (aging at 60 °C-65 °C) Oxidizer Batch aged at 60 "C to 65 JCExample Aging time at 60-65 °C (d)؛ ( Total (P=Ocontent(%)PH Conductivity (uS/cm)3.2 O1 15.0 7.31 1863.3 1 8.3 6.34 12153.4 3 1.5 6.21 17183.5 10 1.3 6.18 19703.6 30 1.2 6.09 2144 1 refers to the point in time when the solution was preparation of the solution was completed.refers to the percentage of molecules having a mass difference of 16 Da relative to the molecular mass of the desired compound determined in mass spectrometry, i.e. percentage of those molecule wherein 1 P=S linkage has been transformed into a P=O linkage.
Claims (9)
1. Process for the production of a mixed P=O/P=S backbone oligonucleotide comprising the oxidation of an intermediary phosphite triester compound of formula I into a phosphodiester compound of formula II according to the scheme 5' nucleoside residue 3' nucleoside residue 5' nucleoside residue 3' nucleoside residue III with an oxidation solution obtained by mixing iodine, an organic solvent and water, characterized in that the oxidation solution has been aged for a time period of at least 1 day, days, 5 days, 10 days, 15 days or at least 20 days at a temperature of 20 °C to 100 °C.
2. Process of claim 1, wherein the organic solvent is pyridine or a C1-6 alkyl-substituted pyridine.
3. Process of claim 2, wherein the volume ratio of pyridine or C1-6 alkyl-substituted pyridine to water is from 1:1 to 20:1, preferably from to 5:1 to 15:1, more preferably is 9:1.
4. Process of claims 2 or 3, wherein the iodine concentration in the oxidation solution is 10 mM to 100 mM, more preferably 20 mM to 50 mM.
5. Process of any one of claim 1 to 4, wherein the aging of the oxidation solution takes place at a temperature of 30 °C to 60 °C.
6. Process of any one of claims 1 to 5, wherein the process comprises the monitoring of the pH and the conductivity to determine the time period that is sufficient to selectively oxidize the phosphite triester compound of formula I into the phosphodiester compound of formula II without converting the phosphorothioate internucleotide linkages.
7. Process of any one of claim 1 to 6, wherein the amount of oxidant used in the oxidation reaction is selected between 1.1 equivalents and 15 equivalents , more preferably 288838/ 02830250102- between 1.5 equivalents and 4.5 equivalents, most preferably between 2 equivalents and equivalents.
8. Process of any one of claim 1 to 7, wherein the reaction temperature for the oxidation reaction is selected between 15 °C and 27 °C, more preferably between 18 °C and °C.
9. Process of any one of claims 1 to 8, wherein the oligonucleotide consists of optionally modified DNA or RNA nucleoside monomers or combinations thereof and is 10 to 40, preferably 10 to 25 nucleotides in length. 10
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19179310 | 2019-06-11 | ||
| PCT/EP2020/065992 WO2020249571A1 (en) | 2019-06-11 | 2020-06-09 | Process for the preparation of oligonucleotides using modified oxidation protocol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL288838A IL288838A (en) | 2022-02-01 |
| IL288838B1 true IL288838B1 (en) | 2025-08-01 |
Family
ID=66821029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL288838A IL288838B1 (en) | 2019-06-11 | 2020-06-09 | Process for preparing oligonucleotides using a modified oxidation protocol |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12606584B2 (en) |
| EP (1) | EP3983421A1 (en) |
| JP (2) | JP2022536157A (en) |
| KR (1) | KR102801138B1 (en) |
| CN (1) | CN113993876B (en) |
| AU (1) | AU2020292763B2 (en) |
| CA (1) | CA3141195C (en) |
| IL (1) | IL288838B1 (en) |
| MX (1) | MX2021015197A (en) |
| TW (1) | TWI848125B (en) |
| WO (1) | WO2020249571A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220133878A (en) | 2020-01-29 | 2022-10-05 | 스미또모 가가꾸 가부시끼가이샤 | Method for preparing nucleic acid oligomers |
| CN115003680B (en) | 2020-01-29 | 2025-01-28 | 住友化学株式会社 | Method for preparing nucleic acid oligomers |
| CN114685572B (en) * | 2022-06-02 | 2022-08-30 | 上海百力格生物技术有限公司 | Oxidant composition for MGB nucleic acid probe synthesis and probe synthesis method |
| WO2026095005A1 (en) * | 2024-10-31 | 2026-05-07 | ペプチスター株式会社 | Production of oligonucleic acid |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ239766A (en) | 1990-09-14 | 1994-05-26 | Hoechst Ag | A process for the chemical synthesis of oligonucleotides |
| US5856464A (en) | 1995-06-07 | 1999-01-05 | Lajolla Pharmaceutical Company | Selective capping solution phase oligonucleotide synthesis |
| US5705621A (en) * | 1995-11-17 | 1998-01-06 | Isis Pharmaceuticals, Inc. | Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same |
| US6518017B1 (en) | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
| US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
| AR036122A1 (en) | 2001-07-03 | 2004-08-11 | Avecia Biotechnology Inc | A COMPLEX OF SALT THAT INCLUDES AN N-ALQUILIMIDAZOL AND A 1,1-DIOXO-1,2-DIHIDRO-1L6-BENZO [D] -ISOTIAZOL-3-ONA AND A METHOD TO SYNTHEIZE OLIGONUCLEOTIDES USING PHOSPHORAMIDITE CHEMISTRY |
| US7205399B1 (en) * | 2001-07-06 | 2007-04-17 | Sirna Therapeutics, Inc. | Methods and reagents for oligonucleotide synthesis |
| US6967247B2 (en) | 2002-07-24 | 2005-11-22 | Isis Pharmaceuticals, Inc. | Deprotection of phosphorus in oligonucleotide synthesis |
| EP2017282A1 (en) | 2006-02-27 | 2009-01-21 | Nippon Shinyaku Co., Ltd. | Method of capping oligonucleic acid |
| JP5320122B2 (en) * | 2009-03-30 | 2013-10-23 | 株式会社小松製作所 | Work vehicle and control method of work vehicle |
| CA2805546A1 (en) | 2010-06-30 | 2012-01-05 | Girindus America, Inc. | A new method of using n-thio compounds for oligonucleotide synthesis |
| EP2823270B1 (en) | 2012-03-09 | 2022-05-04 | Promega Corporation | pH SENSORS |
| WO2018019799A2 (en) | 2016-07-27 | 2018-02-01 | F. Hoffmann-La Roche Ag | Oligonucleotide synthesis |
| CN110573626B (en) | 2017-04-28 | 2024-05-03 | 豪夫迈·罗氏有限公司 | Antibody selection methods |
| CN107474091B (en) | 2017-07-21 | 2019-08-23 | 南开大学 | The synthesis and application of 5- aldehyde radical cytidine phosphoramidite monomer of photosensitive protective group protection and preparation method thereof and oligonucleotide |
| US20220251128A1 (en) * | 2019-05-17 | 2022-08-11 | Ionis Pharmaceuticals, Inc. | Synthesis of oligomeric compounds comprising phosphorothioate diester and phosphodiester linkages |
-
2020
- 2020-06-09 EP EP20732192.8A patent/EP3983421A1/en active Pending
- 2020-06-09 AU AU2020292763A patent/AU2020292763B2/en active Active
- 2020-06-09 IL IL288838A patent/IL288838B1/en unknown
- 2020-06-09 CA CA3141195A patent/CA3141195C/en active Active
- 2020-06-09 JP JP2021573324A patent/JP2022536157A/en active Pending
- 2020-06-09 CN CN202080042718.0A patent/CN113993876B/en active Active
- 2020-06-09 WO PCT/EP2020/065992 patent/WO2020249571A1/en not_active Ceased
- 2020-06-09 US US17/617,819 patent/US12606584B2/en active Active
- 2020-06-09 MX MX2021015197A patent/MX2021015197A/en unknown
- 2020-06-09 KR KR1020217040546A patent/KR102801138B1/en active Active
- 2020-06-10 TW TW109119484A patent/TWI848125B/en active
-
2024
- 2024-05-29 JP JP2024086815A patent/JP7798962B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022536157A (en) | 2022-08-12 |
| AU2020292763B2 (en) | 2022-12-08 |
| TWI848125B (en) | 2024-07-11 |
| TW202112795A (en) | 2021-04-01 |
| MX2021015197A (en) | 2022-01-18 |
| JP7798962B2 (en) | 2026-01-14 |
| US20230295207A1 (en) | 2023-09-21 |
| BR112021025026A2 (en) | 2022-01-25 |
| CA3141195C (en) | 2023-12-19 |
| US12606584B2 (en) | 2026-04-21 |
| EP3983421A1 (en) | 2022-04-20 |
| IL288838A (en) | 2022-02-01 |
| WO2020249571A1 (en) | 2020-12-17 |
| CA3141195A1 (en) | 2020-12-17 |
| CN113993876B (en) | 2024-06-14 |
| JP2024112974A (en) | 2024-08-21 |
| KR102801138B1 (en) | 2025-04-25 |
| AU2020292763A1 (en) | 2022-01-20 |
| KR20220007665A (en) | 2022-01-18 |
| CN113993876A (en) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7798962B2 (en) | Method for preparing oligonucleotides using a modified oxidation protocol | |
| US6114519A (en) | Synthesis of sulfurized oligonucleotides | |
| US20240092823A1 (en) | Process for the de-tritylation of oligonucleotides | |
| AU2022291626A1 (en) | Improved process for preparing imetelstat | |
| JP7777576B2 (en) | Method for the preparation of oligonucleotides using a modified oxidation protocol | |
| Perez-Rentero et al. | Novel oligonucleotide analogues containing a morpholinoamidine unit | |
| HK40085830A (en) | Process for the preparation of oligonucleotides using modified oxidation protocol | |
| HK40060364A (en) | Process for the preparation of oligonucleotides using modified oxidation protocol | |
| WO2026082783A1 (en) | Synthesis of thiolated oligonucleotides without capping and without recirculation of the thiolating agent | |
| HK40085830B (en) | Process for the preparation of oligonucleotides using modified oxidation protocol | |
| Sobczak et al. | DNA oligonucleotides with stereodefined phenylphosphonate and phosphonothioate internucleotide bonds: synthesis and physico-chemical properties. | |
| Wengel et al. | Chemistry of Locked Nucleic Acids (LNA) Design, Synthesis and Bio-Physical Properties | |
| JP2011517695A (en) | Novel process for producing oligonucleotides containing 5'-phosphate monoester or 5'-thiophosphate monoester ends | |
| JPH04330093A (en) | Production of oligoribonucleotide | |
| WO2002083702A1 (en) | Process for selective n-acylation of purine nucleosides | |
| HK40026576A (en) | Improved process for preparing imetelstat | |
| Porcher et al. | Chemical Synthesis of DNA and RNA Containing Modified Nucleotides |